Chronic Thromboembolic Pulmonary Hypertension
Conditions
Brief summary
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension
Detailed description
Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery. Only 4% of patients with acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension and acute pulmonary embolism or deep vein thrombosis is reported in the anamnesis of 75% of those with chronic thromboembolic disease. Therefore, the etiology of the disease is not clear. Altought many studies are done, especially the role of inflamation is emhasised underlie the disease. Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension. Matrix metalloprotinase enzymes are known to play a role in atherosclerosis. This research will investigate whether there is atherosclerosis together with inflamattion in the background of chronic thromboembolic hypertension.
Interventions
OTHERmatrix metalloproteinase enzymes 2 and 9
concentration of matrix metalloproteinase 2 and 9 enzymes
Sponsors
AHMET ZENGIN
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Despite 3 months of anticoagulation therapy * mean pulmonary arterial pressure \> 20 mmHg * pulmonary vasculary resistance \> 3 wood * pulmonary capillary wedge pressure \< 15 mmHg * perfusion defect in ventilation perfusion scintigraphy * pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions
Exclusion criteria
* Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery * Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | 1 year | Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques. |
Countries
Turkey (Türkiye)
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| PATİENT GROUP(GROUP 1) This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes | 24 |
| CONTROL GROUP(GROUP 2) This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.
matrix metalloproteinase enzymes 2 and 9: concentration of matrix metalloproteinase 2 and 9 enzymes | 24 |
| Total | 48 |
Baseline characteristics
| Characteristic | CONTROL GROUP(GROUP 2) | Total | PATİENT GROUP(GROUP 1) |
|---|---|---|---|
| Age, Continuous age | 57.8 years STANDARD_DEVIATION 15.4 | 53.42 years STANDARD_DEVIATION 12.9 | 49.04 years STANDARD_DEVIATION 10.8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 24 Participants | 48 Participants | 24 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| height | 166.7 cm STANDARD_DEVIATION 7.6 | 166.65 cm STANDARD_DEVIATION 8.9 | 166.6 cm STANDARD_DEVIATION 10.2 |
| Region of Enrollment Turkey | 24 participants | 48 participants | 24 participants |
| Sex: Female, Male Female | 8 Participants | 19 Participants | 11 Participants |
| Sex: Female, Male Male | 16 Participants | 29 Participants | 13 Participants |
| Weight | 73.5 kg STANDARD_DEVIATION 13.9 | 79.45 kg STANDARD_DEVIATION 14.05 | 85.4 kg STANDARD_DEVIATION 14.2 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Concentration of Matrix Metalloproteinase 2 and 9 Enzymes
Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.
Time frame: 1 year
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| PATİENT GROUP(GROUP 1) | Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | PRO MMP 2 | 89289.89 ng/ml | Standard Deviation 84639.26 |
| PATİENT GROUP(GROUP 1) | Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | ACTİVE MMP 2 | 205707.83 ng/ml | Standard Deviation 388888.77 |
| PATİENT GROUP(GROUP 1) | Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | MMP 9 | 88975.83 ng/ml | Standard Deviation 94129.68 |
| CONTROL GROUP(GROUP 2) | Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | PRO MMP 2 | 86548.72 ng/ml | Standard Deviation 45312.33 |
| CONTROL GROUP(GROUP 2) | Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | ACTİVE MMP 2 | 152911.57 ng/ml | Standard Deviation 44400.16 |
| CONTROL GROUP(GROUP 2) | Concentration of Matrix Metalloproteinase 2 and 9 Enzymes | MMP 9 | 182029.76 ng/ml | Standard Deviation 140527.87 |
p-value: <0.05t-test, 2 sided